Will the FTC require divestitures or impose conditions on the K-C/KVUE merger?

K-C and KVUE operate in adjacent but distinct consumer health/household categories. The combination creates a very large consumer products company. FTC has been more aggressive on large mergers in recent years. However, category overlaps are limited — K-C is primarily paper/tissue products while KVUE is OTC health and personal care. The IFP business sale may pre-empt concerns. Divestitures are more likely than an outright block, and some form of conditions is common in deals this size. Slightly above 50% for some conditions being imposed.

The key question is whether K-C's IFP business sale constitutes a preemptive remedy. If K-C is already divesting a business to finance the deal and that divestiture addresses potential overlap areas, the FTC may view this as sufficient. Consumer health and household products have enough differentiation that market definition battles may favor the parties. The 96-99% shareholder approval from both sides suggests legal advisors believe regulatory path is clear. Leaning slightly below 50% for conditions.

The FTC under current administration has challenged more mergers than historical norms, but primarily in markets with clear horizontal overlap (grocery, tech). K-C/KVUE is more of a conglomerate/adjacent-category combination. Wound care (Band-Aid vs K-C healthcare) is the most plausible overlap area. Some form of minor divestiture or behavioral remedy is possible but not certain. The combined entity's retail channel power (shelf space across household + health categories) could raise vertical concerns but this is less common. Low confidence due to FTC unpredictability.

K-C is fundamentally a paper/tissue/diaper company; KVUE is OTC health and beauty. The category overlap is minimal. The FTC would need to define markets very broadly (e.g., 'consumer retail shelf space') to find competition concerns. The IFP sale removes one potential overlap. Most comparable consumer staples mergers have cleared without conditions. The current FTC is aggressive but tends to focus on tech, grocery, and healthcare provider markets.

For a ~$22B+ deal combining two top-20 consumer staples companies, some FTC scrutiny is guaranteed. The question is whether scrutiny converts to conditions. Historical base rate for large consumer staples mergers receiving conditions is perhaps 30-40%. The K-C/KVUE combination is more complementary than competitive, which lowers the probability. But the wound care overlap (Band-Aid + K-C healthcare products) and baby care (Johnson's Baby + Huggies/Pull-Ups adjacency) could draw attention. Minor divestitures are more likely than major conditions.

The strongest signal is that both companies' legal teams and boards approved with 96-99% shareholder support. This level of confidence typically reflects robust antitrust analysis. The IFP sale appears designed to address any residual overlap concerns. While the FTC could surprise, the limited horizontal overlap makes conditions unlikely. Probability below 40%.

K-C and KVUE are in different product categories. FTC typically requires conditions only for horizontal overlaps. Consumer staples mergers have historically cleared with minimal conditions. IFP sale further reduces concerns. Below 40% probability.

Large deal size and current FTC stance could generate some conditions, even with limited overlap. Wound care is the most plausible area for concern. But the fundamental category differences between tissue/diapers and OTC health make a strong case for clearance. Low confidence due to FTC unpredictability under current leadership.

Complementary combination with limited overlap. Both boards and shareholders strongly approved. IFP sale proactively addresses concerns. FTC may issue second request but unlikely to require material conditions or block. 37% probability for any conditions.